An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

915

Enrollment

INDUSTRY

Sponsor class

Conditions

High-risk Muscle Invasive Urothelial Carcinoma

Interventions

DRUG: Dato-DXd
DRUG: Rilvegostomig
DRUG: Durvalumab
DRUG: Nivolumab
DRUG: Pembrolizumab
DRUG: Enfortumab vedotin

Sponsor

AstraZeneca

Collaborators

[object Object]